Bristol Myers Squibb

News

Largest BMS shareholder opposes Celgene deal

Bristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future of the deal in doubt.

News

BMS looks to RNA splicing to boost immunotherapies

Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and its US-based precision medicine subsidiary H3 Biomedicine to

News

NHS funds BMS' Opdivo to prevent skin cancer returning

NICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer from recurring, overturning a decision earlier this year

News

Known as Cabometyx in the US, the drug is licensed by Ipsen from Exelixis

EU approves Ipsen's Cabometyx in second line liver cancer

The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar.

News

BMS, AbbVie get FDA OK for new myeloma regimen

Bristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they hope will help drive uptake of the drug.

News

BMS and Infinity trial immunotherapy combo in bladder cancer

Bristol-Myers Squibb has broadened a collaboration with Infinity Pharmaceuticals as it seeks to find combinations that boost the potency of its cancer immunotherapy, Opdivo.

Largest BMS shareholder opposes Celgene deal

BMS looks to RNA splicing to boost immunotherapies

NHS funds BMS' Opdivo to prevent skin cancer returning

EU approves Ipsen's Cabometyx in second line liver cancer

BMS, AbbVie get FDA OK for new myeloma regimen

BMS and Infinity trial immunotherapy combo in bladder cancer

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks